Why should the clonogenic cell assay be prognostically important in ovarian cancer? 1991

S A Cannistra

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014410 Tumor Stem Cell Assay A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents. Clonogenic Cell Assay, Tumor,Colony-Forming Units Assay, Tumor,Neoplasm Stem Cell Assay,Stem Cell Assay, Tumor,Colony Forming Units Assay, Tumor

Related Publications

S A Cannistra
April 1983, American family physician,
S A Cannistra
January 2005, Methods in molecular medicine,
S A Cannistra
August 1955, Medical times,
S A Cannistra
July 1987, The Korean journal of internal medicine,
S A Cannistra
April 2023, Reproductive biomedicine online,
S A Cannistra
January 1999, Methods in molecular medicine,
S A Cannistra
January 2004, Methods in molecular medicine,
S A Cannistra
May 2001, The Johns Hopkins medical letter health after 50,
S A Cannistra
June 1986, Der Gynakologe,
Copied contents to your clipboard!